A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Oprah Winfrey is sparking a debate around weight, willpower and perception after the media mogul revealed her perceptions ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

An anxious generation turns to functional foods and beverages and alternative medicine, inspiring better-for-you innovation.

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.